Search - tctmd.com

Displaying 161 - 176 of 176

Sort: Relevancy | Date

News Conference News AHA 2015

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Todd Neale

November 12, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

September 11, 2015

News Conference News ESC 2015

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

September 09, 2015

News Industry News

Boston Heart Reaches Milestone in Statin Intolerance Testing

September 08, 2015

News Industry News

FDA approves Repatha to treat certain patients with high cholesterol

August 28, 2015

News Daily News

钙化评分为零“保证”了无症状患者 15 年死亡率

August 06, 2015

News Daily News

Zero Calcium Score Provides 15-Year Mortality ‘Warranty’ for Asymptomatic Patients

August 06, 2015

News Daily News

Una Puntuación de Calcio Igual a 0 Ofrece una ‘Ventaja’ sobre la Mortalidad de 15 Años de Duración en Pacientes Asintomáticos

August 06, 2015

News Industry News

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

July 24, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Daily News

IMPROVE-IT结果发布：对于向他汀类疗法中添加依泽替米贝是否有帮助进行了热烈的辩论

Yael L. Maxwell

June 05, 2015

News Daily News

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

Yael L. Maxwell

June 05, 2015

News Industry News

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

June 05, 2015

News Daily News

Poor Responders to Statins at Risk for CAD Progression

March 11, 2015

Advertisement

Degree of LDL Cholesterol-Lowering on High-Intensity Rosuvastatin Determines Clinical Impact

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff

Boston Heart Reaches Milestone in Statin Intolerance Testing

FDA approves Repatha to treat certain patients with high cholesterol

钙化评分为零“保证”了无症状患者 15 年死亡率

Zero Calcium Score Provides 15-Year Mortality ‘Warranty’ for Asymptomatic Patients

Una Puntuación de Calcio Igual a 0 Ofrece una ‘Ventaja’ sobre la Mortalidad de 15 Años de Duración en Pacientes Asintomáticos

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

IMPROVE-IT结果发布：对于向他汀类疗法中添加依泽替米贝是否有帮助进行了热烈的辩论

IMPROVE-IT Published: Hotly Debated Ezetimibe Helpful When Added to Statin Therapy

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

Poor Responders to Statins at Risk for CAD Progression

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content